NASDAQ:ZBIO Zenas BioPharma Q2 2025 Earnings Results & Report $23.85 -1.19 (-4.75%) Closing price 04:00 PM EasternExtended Trading$23.85 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zenas BioPharma missed analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$1.25 versus the -$1.02 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market OpensConference Call7:00 AM ET Zenas BioPharma EPS ResultsActual EPS-$1.25Consensus EPS -$1.02Beat/MissMissed by -$0.23One Year Ago EPSN/AEPS Beat Rate2 of last 7 quartersZenas BioPharma Revenue ResultsActual RevenueN/AExpected Revenue$5 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zenas BioPharma Q2 2025 Earnings FAQ Did Zenas BioPharma beat earnings estimates for Q2 2025? Zenas BioPharma (NASDAQ:ZBIO) reported earnings of -$1.25 per share for Q2 2025, missing the consensus estimate of -$1.02. The report was announced on Tuesday, August 12, 2025. Zenas BioPharma Earnings HeadlinesZenas BioPharma Announces Inducement Grants to Newly Hired EmployeesNovember 18 at 4:31 PM | quiverquant.comQZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 18 at 4:15 PM | globenewswire.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.November 20 at 1:00 AM | Decentralized Masters (Ad)Zenas BioPharma Launches The Distance Between Platform to Bring Greater Visibility to the Hidden Burden of IgG4-Related DiseaseNovember 17 at 7:00 AM | globenewswire.comFY2026 EPS Forecast for Zenas BioPharma Decreased by AnalystNovember 13, 2026 | americanbankingnews.comZenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on WednesdayNovember 11, 2026 | americanbankingnews.comSee More Zenas BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email. Email Address About Zenas BioPharmaZenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business.Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.The company is led by co-founder and Chief Executive Officer Hua Mu, who has experience in the biopharmaceutical industry. Zenas’s development efforts are aimed at patients with immune-mediated diseases for which existing treatment options may be limited.View Zenas BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.